Shanghai Pharmaceuticals Holding , Ltd Receivables

The latest receivables for SHPMY is $100B as of September 2026. That compares with $94B in the prior-year period — up 6.6% year over year. Investors often review this figure alongside Shanghai Pharmaceuticals Holding , Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, SHPMY's receivables moved from $94B to $100B — a 6.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Shanghai Pharmaceuticals Holding , Ltd's operating scale or balance-sheet position.

A receivables figure of $100B for SHPMY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SHPMY's receivables ($100B), review year-over-year change from $94B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.